ROR Inhibitor

huXBR1-402 (NBE-002 Antibody) is a high-affinity (K_d=5.8 nM) humanized chimeric rabbit/human monoclonal antibody that targets ROR1. huXBR1-402 specifically binds to the Ig/Fz domain epitope of human ROR1, directly inhibits the proliferation of ROR1-positive tumor cells and induces apoptosis of leukemia cells (apoptosis).

RORγ-IN-3 (Compound 21) is a potent and highly selective RORγ inhibitor with an EC₅₀ of 84 nM. RORγ-IN-3 can effectively inhibit the production of IL-17, with an IC₅₀ value of 1.0 μM. RORγ-IN-3 can be used for the study of autoimmune diseases.

RORγt inverse agonist 34 (compound 5a) is a RORγt inverse agonist with an IC₅₀ of 0.094 μM for RORγt-LBD. RORγt inverse agonist 34 is used for psoriasis research.

ROR1-IN-3 (Compound 24d) is a potent and highly selective ROR1 kinase inhibitor (IC₅₀ = 17.6 nM). ROR1-IN-3 demonstrates robust antitumor activity and inhibitory effect against ROR1 both in vitro and in vivo. ROR1-IN-3 has robust antiproliferative efficacy in vitro and in vivo. ROR1-IN-3 induces apoptosis in cancer cell lines. ROR1-IN-3 inhibits ROR1 downstream AKT/mTOR and NF-κB signaling pathway. ROR1-IN-3 can be studied in antitumor research.

RORγt inverse agonist 32 (compound b14) is orally active. RORγt inverse agonist 32 can be used in inflammation research.

BMS-336 (Compound 89) is a RORγ inhibitor. BMS-336 can be used for the research of cancer.

RORγt inverse agonist 29 is a potent, orally active and selective RORγt inverse agonist (IC₅₀: 21 nM). RORγt inverse agonist 29 can be used in the research of skin inflammation and autoimmune diseases like psoriasis.

RORγt inhibitor 2 (Compound 119) is a potent RORγt inhibitor with an IC₅₀ of 9.2 nM. RORγt inhibitor 2 can be used for the research of cancer, inflammation or autoimmune diseases mediated by RORγt.

Rorb Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rorb gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

RORγ-IN-2 (Compound 22) is a RORγ inhibitor, with a K_i of 16.6 nM for hRORγ. RORγ-IN-2 can be used for the research of IL-17-dependent autoimmune diseases.

RORγt inverse agonist 36 (S configuration of Compound 16) is a RORγt inverse agonist. RORγt inverse agonist 36 can be used for the research of inflammation and immunology.

ROR1-IN-4 is a selective ROR1 inhibitor with a K_d of 52 nM. ROR1-IN-4 shows potent anti-proliferative activity against TNBC cell line MDA-MB-231 (IC₅₀ = 75 nM). ROR1-IN-4 reduces colony formation, induces apoptosis and inhibits the phosphorylation of ROR1 (Tyr786) in MDA-MB-231 cells. ROR1-IN-4 demonstrates superior anti-tumor efficacy in nude mice bearing MDA-MB-231 subcutaneous xenografts. ROR1-IN-4 can be used for the study of triple-negative breast cancer (TNBC).

RORγ-IN-4 is a RORγ inhibitor with an EC₅₀ of 0.014 μM. RORγ-IN-4 can be used for the research of inflammation.

SR1001 (Standard) is the analytical standard of SR1001. This product is intended for research and analytical applications. SR1001 is a selective RORα and RORγt inverse agonist with Kis 172 and 111 nM, respectively.

CID 7309015 is an inhibitor of retinoic acid-related orphan receptor gamma (ROR-γ). CID 7309015 can be used for research of inflammation, NF-κB signaling or inflammatory arthritis.

RORγt inhibitor 3 is an orally active and potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor. RORγt inhibitor 3 shows high binding affinity and inhibitory activity of Th17 cell differentiation. RORγt inhibitor 3 also shows efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models.

RORγ/DHODH-IN-1 (compound 1404), a deuterium labeled compound, is a dual RORγ and DHODH inhibitor with IC₅₀ values of 9.7 nM and 100 nM, repaectively. RORγ/DHODH-IN-1 blocks the replication of SARS-CoV-2, HCMV, and non-enveloped DNA virus (HAdV5).

Vimirogant hydrobromide (VTP-43742 hydrobromide) is a potent, selective, and orally active RORγt inhibitor with a K_i of 3.5 nM for binding to RORγt. VTP-43742 blocks Th17 cell differentiation and reduces IL-17A production by inhibiting RORγt-mediated transcriptional activity, thereby suppressing the RORγt/Th17/IL-17 inflammatory axis. VTP-43742 can be used for research on autoimmune diseases and inflammation-related diseases.

RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC₅₀ values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC₅₀ values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively.

Vimirogant (VTP-43742) is a potent, selective, and orally active RORγt inhibitor with a K_i of 3.5 nM for binding to RORγt. VTP-43742 blocks Th17 cell differentiation and reduces IL-17A production by inhibiting RORγt-mediated transcriptional activity, thereby suppressing the RORγt/Th17/IL-17 inflammatory axis. VTP-43742 can be used for research on autoimmune diseases and inflammation-related diseases.